Sign up to save your podcasts
Or
Share New Interview with CEO of BriaCell Therapeutics Corp.
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
New Interview with CEO of BriaCell Therapeutics Corp.
SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Dr. Bill Williams, CEO of BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT), to discuss three key achievements that support the Company’s continued growth. The Company recently announced positive initial efficacy data in its 2021-2022 cohort of 12 advanced breast cancer patients. Disease control, tumor shrinkage, and potential survival benefit were observed amongst 12 patients in the Phase I/IIa clinical study of Bria-IMT in combination with Incyte’s retifanlimab.
Bria-IMT regimen in combination with Incyte’s retifanlimab produced evidence of disease control, tumor shrinkage, and potential survival benefit amongst BriaCell’s recent 12 patient cohort in advanced breast cancer. The study, recently awarded U.S. Food and Drug Administration ("FDA") fast track designation, continues with additional clinical data forthcoming.
The regimen remains well tolerated as recently reported in Phase I evaluation.
70% of patients showed either disease control or progression-free survival (PFS) benefits compared with their last therapy.
Prior to enrollment, the 12 patients in the cohort had already been unsuccessfully heavily pre-treated with at least 2 prior therapy regimens, further underscoring BriaCell’s positive patient outcomes.
View all episodes
By Stuart SmithSmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Dr. Bill Williams, CEO of BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT), to discuss three key achievements that support the Company’s continued growth. The Company recently announced positive initial efficacy data in its 2021-2022 cohort of 12 advanced breast cancer patients. Disease control, tumor shrinkage, and potential survival benefit were observed amongst 12 patients in the Phase I/IIa clinical study of Bria-IMT in combination with Incyte’s retifanlimab.
Bria-IMT regimen in combination with Incyte’s retifanlimab produced evidence of disease control, tumor shrinkage, and potential survival benefit amongst BriaCell’s recent 12 patient cohort in advanced breast cancer. The study, recently awarded U.S. Food and Drug Administration ("FDA") fast track designation, continues with additional clinical data forthcoming.
The regimen remains well tolerated as recently reported in Phase I evaluation.
70% of patients showed either disease control or progression-free survival (PFS) benefits compared with their last therapy.
Prior to enrollment, the 12 patients in the cohort had already been unsuccessfully heavily pre-treated with at least 2 prior therapy regimens, further underscoring BriaCell’s positive patient outcomes.